IBD Research Unit
PICaSO
PICaSO is a randomized control trial that is exploring a new method of improving outcomes of patients undergoing major surgery for GI cancers, known as prehabilitation. Prehabilitation involves improving a patient’s physical and mental conditioning before surgery to hopefully improves outcomes after major surgery. PICaSO will investigate the effects of prehabilitation on health-related quality of life, length of stay, ad post-operative complications. Patients will be randomized to either the Prehabilitation Arm or the Control Arm (usual care). The prehab arm will be prescribed both physical and psychological prehab prior to undergoing surgery for their GI cancer. The usual care group will be counseled to continue their current level of activity and given the information on exercise as outlined in the Cancer Care Ontario guidelines. Patients in both trial arms will be given the same Fitbit activity tracker in order to eliminate the activity tracker as an intervention itself and to be able to track the activity levels of both patient groups for comparison. Clinical, patient-reported outcomes and health system outcomes will be evaluated. Outcomes will be measured at consent (baseline), immediately preoperatively, and postoperatively at 1, 3 and 6 months.
This method of prehabilitation could represent a paradigm shift in the way we currently prepare cancer patients for surgery; therefore, this study has the potential to significantly improve patient outcomes. Dr. Anand Govindarajan, Surgical Oncologist, is the Sponsor-Investigator for the PICaSO trial. Recruitment for the trial will be happening at both Mount Sinai Hospital and the University Health Network.
If you are a patient on trial or have any questions regarding the trial, please contact (416) 586-4800 x4990
PICaSO Surveys
PICaSO Baseline
https://ddcrc.mshri.on.ca/NoviSurvey/n/Demographic.aspx
https://ddcrc.mshri.on.ca/NoviSurvey/n/EORTCQLQC30.aspx
https://ddcrc.mshri.on.ca/NoviSurvey/n/GLTExercise.aspx
https://ddcrc.mshri.on.ca/NoviSurvey/n/ESAS.aspx
https://ddcrc.mshri.on.ca/NoviSurvey/n/EQ5D.aspx
https://ddcrc.mshri.on.ca/NoviSurvey/n/WLQ.aspx
https://ddcrc.mshri.on.ca/NoviSurvey/n/ECRM16.aspx
https://ddcrc.mshri.on.ca/NoviSurvey/n/MOSSF20.aspx
https://ddcrc.mshri.on.ca/NoviSurvey/n/FACITF.aspx
https://ddcrc.mshri.on.ca/NoviSurvey/n/HADS.aspx
PICaSO 1 Month
https://ddcrc.mshri.on.ca/NoviSurvey/n/EORTCQLQC30.aspx
https://ddcrc.mshri.on.ca/NoviSurvey/n/GLTExercise.aspx
https://ddcrc.mshri.on.ca/NoviSurvey/n/ESAS.aspx
https://ddcrc.mshri.on.ca/NoviSurvey/n/EQ5D.aspx
https://ddcrc.mshri.on.ca/NoviSurvey/n/WLQ.aspx
https://ddcrc.mshri.on.ca/NoviSurvey/n/ECRM16.aspx
https://ddcrc.mshri.on.ca/NoviSurvey/n/MOSSF20.aspx
https://ddcrc.mshri.on.ca/NoviSurvey/n/FACITF.aspx
https://ddcrc.mshri.on.ca/NoviSurvey/n/HADS.aspx
PICaSO 3 Month & 6 Month
https://ddcrc.mshri.on.ca/NoviSurvey/n/EORTCQLQC30.aspx
https://ddcrc.mshri.on.ca/NoviSurvey/n/GLTExercise.aspx
https://ddcrc.mshri.on.ca/NoviSurvey/n/ESAS.aspx
https://ddcrc.mshri.on.ca/NoviSurvey/n/EQ5D.aspx
https://ddcrc.mshri.on.ca/NoviSurvey/n/WLQ.aspx
https://ddcrc.mshri.on.ca/NoviSurvey/n/ECRM16.aspx
https://ddcrc.mshri.on.ca/NoviSurvey/n/MOSSF20.aspx
https://ddcrc.mshri.on.ca/NoviSurvey/n/FACITF.aspx
https://ddcrc.mshri.on.ca/NoviSurvey/n/HADS.aspx
https://ddcrc.mshri.on.ca/NoviSurvey/n/HSSU.aspx
PSM Database
https://ddcrc.mshri.on.ca/NoviSurvey/n/QLQC30.aspx
https://ddcrc.mshri.on.ca/NoviSurvey/n/QLQCR29.aspx
PSM Database + QLACS
https://ddcrc.mshri.on.ca/NoviSurvey/n/QLQC30.aspx
Peer Support Program
The Familial Gastrointestinal Cancer Registry (FGICR) is committed to offering support to families with hereditary gastrointestinal cancer and polyposis syndromes. An important part of this support is our ability to connect people who share the same hereditary conditions. Individuals and families involved in the FGICR have found it very helpful to connect through the Peer Support Program, and have benefited from sharing experiences with each other. Research has also shown peer support programs to have social and emotional benefits.
As these hereditary conditions may be rare, we would greatly appreciate if you would be willing to be included in our Peer Support Program (aka. Buddy System). This program matches people based on diagnosis and other factors. Matches are made on request, and have been particularly helpful at the time of a new diagnosis, around the time of a surgery, and when parents have concerns about their children.
If you are willing to be included in our Peer Support Program, please download the form here and complete it and either print the file and mail it to us or save it to your desktop and email it to us.
| Mailing address | ||
Zane Cohen Centre for Digestive Diseases Familial Gastrointestinal Cancer Registry Mount Sinai Hospital Joseph and Wolf Lebovic Health Complex Box 24 - 60 Murray Street Toronto, ON M5T 3L9 |
FGICR.MSH@SinaiHealth.ca |
Email Consent
We always strive to make sure that you receive the latest information about what the Zane Cohen Centre is doing and we want to take the green initiative to reduce paper usage. We would love to send you newsletter updates and the latest information about research conducted at the Zane Cohen Centre by email. Your email will not be shared with any other parties and will only be exclusively used for receiving information updates from the Zane Cohen Centre. If you are interested in joining our email list, please register online here: Link
There will be the option to unsubscribe on all communication items and you can contact us by email: ZaneCohenCentre.MSH@SinaiHealth.ca or by phone: 416-586-5112 or toll free 1-877-586-5112.
Sincerely,
Zane Cohen Centre Administration
www.zanecohencentre.com
Pancreatic Mutation Identification Survey
Dear Genetic Counsellor:
In this survey, you will be shown twenty to twenty-five real pedigrees where the proband has been diagnosed with pancreatic cancer and asked to provide an estimate from 0 to 100% of the likelihood that the proband carries a pathogenic mutation in BRCA1 or BRCA2. These probands were recruited prospectively in an unselected manner from a multidisciplinary pancreatic cancer clinic. You will also be asked to provide basic demographic data.
All probands have been diagnosed with pancreatic adenocarcinoma. Where there was additional pathological information, for example, rhabdoid features, this is also provided.
Each proband's ethnicity is provided. Ashkenazi Jewish probands are specifically identified as such.
Cancer diagnoses are provided under the individuals in the pedigrees as "diagnosis age (source of diagnosis)", for instance, "pancreatic adenocarcinoma 86 (PA)". The source of diagnosis is as follows:
PA: Pathology reports
MR: Medical record
HX: History alone
AR: Autopsy report
DC: Death certificate
OCR: Ontario Cancer Registry.
Otherwise, the pedigrees follow the recommended nomenclature of the National Society of Genetic Counsellors.
|
Click on this link to go to the survey: https://ddcrc.mshri.on.ca/NoviSurvey/n/bipac8.aspx |
If the survey has been answered the maximum number of times, please refresh this page and try the next survey
Sincerely,
Robert Grant, Spring Holter, Ayelet Borgida, and Steven Gallinger
Mount Sinai Hospital, Toronto, Canada.